Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Except Non Small Cell Lung Cancer,Including Liver Cancer,Gastric Cancer,Esophageal Cancer and so on

Next Previous
X
Search
Trial Profile

Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Except Non Small Cell Lung Cancer,Including Liver Cancer,Gastric Cancer,Esophageal Cancer and so on

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TAEST 16001 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Advanced breast cancer; Bladder cancer; Bone cancer; Carcinoma; Gastric cancer; Liver cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 20 Jan 2020 Status changed from recruiting to completed.
    • 14 Jan 2019 Treatment change- interleukin-2 subcutaneous injection is removed from the treatment. Lymphodepleting regimen pretreatment with fludarabine and cyclophosphamide is added.
    • 14 Jan 2019 Planned End Date changed from 31 May 2019 to 31 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top